Cynata Therapeutics (ASX:CYP) Price-to-Free-Cash-Flow : N/A (As of Jun. 07, 2024)

Cynata Therapeutics Price-to-Free-Cash-Flow Chart

Cynata Therapeutics Annual Data
	Trend	Jun14	Jun15	Jun16	Jun17	Jun18	Jun19	Jun20	Jun21	Jun22	Jun23
Price-to-Free-Cash-Flow		Get a 7-Day Free Trial					-	-	-	-	-

Cynata Therapeutics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Price-to-Free-Cash-Flow	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Cynata Therapeutics's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Cynata Therapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cynata Therapeutics's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cynata Therapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Cynata Therapeutics's Price-to-Free-Cash-Flow falls into.

Cynata Therapeutics Price-to-Free-Cash-Flow Calculation

Cynata Therapeutics's Price-to-Free-Cash-Flow ratio for today is calculated as

Cynata Therapeutics's Share Price of today is A$0.30.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cynata Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.08.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Cynata Therapeutics  (ASX:CYP) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.

Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.

Cynata Therapeutics Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Cynata Therapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Cynata Therapeutics (ASX:CYP) Business Description